SE

S. Eric Innis

Chief Medical Officer

InMed Pharmaceuticals

Therapeutic Areas

InMed Pharmaceuticals Pipeline

DrugIndicationPhase
INM-755Epidermolysis Bullosa (wound care)Phase 2
INM-088GlaucomaPreclinical